ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Hikal reported Q1 FY27 revenue of Rs 403 Cr with 9.2% EBITDA margin. Results show recovery post-regulatory disruption, driven by Pharma and Animal Health scaling.
Hikal reported Q1FY27 revenue of ₹403 Cr, up 6% YoY. Focus remains on pharma remediation and commissioning the Panoli facility for Personal Care.
Q4FY26 revenue hit ₹519cr with 20.3% EBITDA margin. Management focuses on transition from remediation to sustainable technology-led growth despite US FDA and raw material headwinds.
Hikal is navigating a difficult recovery phase, masked by a massive ₹47cr impairment and USFDA warning letter at Bangalore. While margins show sequential improvement, the core business remains stagnant and heavily reliant on regulatory resolution.
Hikal reported Q4 FY26 revenue of Rs 519 Cr with a 20.3% EBITDA margin. Full year FY26 revenue reached Rs 1,713 Cr, though exceptional items led to a consolidated net loss of Rs 49 Cr.